Certolizumab pegol
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
... agents, certolizumab pegol is associated with an increased risk of tubercu- losis, not only in countries with a high incidence of ...with certolizumab 200 mg and cer- tolizumab 400 mg (Peto OR ...
204
4 year results from the RAPID PsA phase 3 randomised placebo controlled trial of certolizumab pegol in psoriatic arthritis
... Figure 1 (A) RAPID-PsA trial design, (B) patient disposition to Week 216 and (C) Kaplan-Meier plot to time of withdrawal for any reason, or due to lack of efficacy or adverse events, for patients randomised to CZP at ...
12
Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
... showed certolizumab pegol + methotrexate to be the second most cost-effective TNF inhibitor after etanercept + methotrexate, dominating infliximab, adalimumab and golimumab combination ther- apies at a WTP ...
13
Early non response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study
... This was a protocol- specified analysis of interim (12- month) data from the ECLAIR (Evaluation de l’évolu- tion des patients traités par certolizumab pegol pour une polyarthrite rhumatoïde en pratique ...
8
Long term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
... CZP, certolizumab pegol; IR, incidence rate; OLE, open-label extension; PBO, placebo; PPD, purified protein derivative; PsA, psoriatic arthritis; PSO, psoriasis; PY, patient-years; RA, rheumatoid arthritis; ...
14
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
... across certolizumab pegol (CZP) clinical trials in rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), before and after the introduction of stricter TB ...
11
New biologics in the management of Crohn’s disease: focus on certolizumab pegol
... on certolizumab pegol, the first Fc-free PEGylated Fab' fragment of human- ized monoclonal antibody that binds and neutralizes human tumor necrosis factor ...disease, certolizumab (CDP870), antiTNF-α ...
8
A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post hoc results from the certolizumab pegol phase 4 PREDICT trial
... The goal of these exploratory, post-hoc analyses was to define a “ somatization comorbidity phenotype ” (SCP) that could classify patients with RA participating in a clinical trial who had one or more conditions (e.g. ...
11
The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
... certolizumab pegol. The results of up to 100 weeks of treatment with certolizumab pegol with an emphasis on functional outcomes, is the focus of this ...
12
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs : a systematic review and economic evaluation
... considering the whole-trial population, SEC was associated with statistically and clinically significant improvements in all key outcomes. Patients taking SEC were around six times more likely to be ACR 50 responders – a ...
375
One year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real world setting: data from a national U S rheumatoid arthritis registry
... Certolizumab pegol (CZP), a PEGylated, Fc-free TNFi, is approved for the treatment of adult patients with moderate to severe active RA [27]. Currently, there is limited evidence on the safety of CZP ...
11
Impact of certolizumab pegol on patient reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity
... Inhibitor Certolizumab pegol) study, which was double- blinded and placebo-controlled to week 12 (randomizing patients in a 4:1 fashion [certolizumab pegol:placebo]) and open-label thereafter, had ...
10
Scintigraphic detection of TNF driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
... (adalimumab, certolizumab, golimumab, in fl iximab) and one receptor-fusion protein (etanercept) are ...8 Certolizumab pegol (CZP; UCB Celltech, Slough, Berkshire, UK) is an engineered humanised ...
11
Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study
... Similar improvements in household productivity were observed in the AS and nr-axSpA subpopulations (figure 4). By week 24, CZP-treated patients with AS reported more household work days gained (on average 2.8 days; ...
11
Twenty eight week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
... CZP: Certolizumab pegol; DAS: Disease activity score; DB: Double-blind; DMARD: Disease-modifying antirheumatic drug; DOSEFLEX: Dosing flexibility; ESR: Erythrocyte sedimentation rate; FAS: Full analysis ...
13
Anti TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling
... CZP: certolizumab pegol; DAPI: 4',6-diamidino-2-phenylindole; DPI: diphenyleneiodonium chloride; EDTA: ethylenediaminetetraacetic acid; GM-CSF: granulocyte-macrophage colony-stimulating factor; HO-1: heme ...
9
Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
... CZP, certolizumab pegol; HAQ-DI, Health Assessment Questionnaire Disability Index; PASI, Psoriasis Area and Severity Index; wk, week; Q2W, every 2 ...
15
Rapid and sustained improvements in health related quality of life, fatigue, and other patient reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial
... of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis ...
12
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
... Certolizumab pegol (CZP) is a PEGylated, Fc-free anti-TNF. The ef fi cacy of CZP in combin- ation with methotrexate (MTX) has been proven in patients with established RA and insuf fi cient response to MTX ...
11
Prefilled certolizumab pegol (Cimzia<sup>®</sup>) syringes for self-use in the treatment of rheumatoid arthritis
... the certolizumab pegol 200-mg group and 400-mg group, ...vs certolizumab pegol 200 mg ...46). Certolizumab pegol conferred rapid improvement in the signs and symptoms of ...with ...
7